<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="363">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01931150</url>
  </required_header>
  <id_info>
    <org_study_id>13-012</org_study_id>
    <nct_id>NCT01931150</nct_id>
  </id_info>
  <brief_title>Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT</brief_title>
  <official_title>A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the investigators can  prevent or reduce the severity
      of the Cetuximab-related acne rash. Two different topical agents will be applied to the
      skin. One topical agent is the dapsone gel and the other is a skin moisturizer.  Dapsone gel
      is an FDA approved medication that you apply to the face. It is commonly used to treat acne.
      Skin moisturizers are recommended to patients who receive Cetuximab treatment. In addition
      to these topical agents they will be given a pill to take once a day. This pill has already
      been shown to help fight rashes from Cetuximab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>difference in lesion counts</measure>
    <time_frame>28 ± 2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lesion counts at day 28 ± 2 days (primary endpoint)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cetuximab-induced Papulopustular (Acneiform) Rash Who Have</condition>
  <condition>Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Dapsone 5% Gel</intervention_name>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Moisturizer</intervention_name>
    <description>The moisturizer for the study will be Vanicream™ Lite Lotion.</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral antibiotics</intervention_name>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years or older with underlying diagnosis of metastatic colorectal cancer
             or head and neck squamous cell carcinoma including newly diagnosed patient

          -  Patients must provide written informed consent to participate in the study

          -  Anticipated initiation of cetuximab treatment with or without additional
             chemotherapy.

          -  Able to self-administer topical interventions or provide for another person to apply
             the topical interventions

        Exclusion Criteria:

          -  Females of childbearing potential who are pregnant or nursing

          -  Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa
             antibiotics, or excipients of the dapsone gel product

          -  Patients with pre-existing dermatologic condition affecting the face and chest  that
             would impair assessment of papulopustular rash including dense and/or long facial
             hair (per investigator discretion)

          -  Patients currently using prescription and/or over-the-counter topical medications to
             the face and/or chest who are unwilling to discontinue use during the trial
             intervention period (day 0 ± 2 days through day 28 ± 2 days)

          -  Previous or concurrent radiation therapy to head, neck, and chest (i.e. application
             sites only)

          -  Previous therapy with cetuximab within 6 months of consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Lacouture, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Lacouture, MD</last_name>
    <phone>212-610-0079</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allan Halpern, MD</last_name>
    <phone>212-610-0766</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Lacouture, MD</last_name>
      <phone>212-610-0079</phone>
    </contact>
    <contact_backup>
      <last_name>Allan Halpern, MD</last_name>
      <phone>212-610-0766</phone>
    </contact_backup>
    <investigator>
      <last_name>Mario Lacouture, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 2, 2015</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topical Dapsone 5% Gel</keyword>
  <keyword>Moisturizer</keyword>
  <keyword>rash</keyword>
  <keyword>13-012</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
